Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

All the headlines: Primary care recovery plan funding details revealed

Find out everything you need to know about how the government will split its £645 million investment into community pharmacy services – plus, the launch dates for Pharmacy First and a new contraception service.

Yesterday (November 16), NHS England (NHSE) and the Department of Health and Social Care (DH) finally announced the details of how it will divide up its £645 million investment in community pharmacy services over two years, first announced as part of the primary care recovery plan in May.

As part of a raft of new information about community pharmacy funding in England, the government also revealed the start dates for the much-anticipated national Pharmacy First service and the expanded pharmacy contraception service.

The main headlines include:

 

Check the C+D site for the latest coverage on this developing story

Related Content

Topics

         
Registrant member of the Assurance and Appointments Committee 
Nationwide
£ Renumeration

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD137451

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel